Table 3.
Disease remission vs. recurrence in revision ESS patients.
| Total: 80 patients | Remission | Recurrence | p-value |
|---|---|---|---|
| Patients | 32 (40%) | 48 (60%) | |
| Age | 52.9 | 50.0 | p = 0.295 |
| Male | 16 (50%) | 26 (54.2%) | p = 0.715 |
| Female | 16 (50%) | 22 (45.8%) | |
| Asthma | 22 (68.8%) | 37 (77.1%) | p = 0.407 |
| Smoking | |||
| Never | 12 (37.5%) | 22 (45.8%) | p = 0.485 |
| Active | 8 (25.0%) | 7 (14.6%) | |
| Former | 12 (37.5%) | 19 (39.6%) | |
| Polyposis | 31 (96.9%) | 42 (87.5%) | p = 0.233 |
| Race | |||
| Caucasian | 28 (87.5%) | 44 (91.7%) | p = 0.321 |
| Hispanic | 1 (3.1%) | 3 (6.3%) | |
| Asian | 1 (3.1%) | 1 (2.1%) | |
| Arabic | 2 (6.3%) | 0 (0.0%) | |
| Allergies (all types) | 28 (87.5%) | 35 (72.9%) | p = 0.118 |
| Seasonal | 14 (43.8%) | 11 (22.9%) | p = 0.049 |
| NSAID | 4 (12.5%) | 16 (33.3%) | p = 0.039 |
| S. aureus (pre-ESS) | 3 (9.7%) | 12 (25%) | p = 0.141 |
| S. aureus (post-ESS) | 3 (10.0%) | 20 (48.8%) | p < 0.001 |
| P. aeruginosa (pre-ESS) | 1 (3.2%) | 5 (10.4%) | p = 0.395 |
| P. aeruginosa (post-ESS) | 0 (0.0%) | 5 (12.2%) | p = 0.069 |
| Gram negative (pre-ESS) | 7 (22.6%) | 11 (22.9%) | p = 1.000 |
| Gram negative (post-ESS) | 5 (16.7%) | 10 (24.4%) | p = 0.560 |
| SNSS (post-ESS) | 4.8 | 5.3 | p = 0.660 |
| SNOT22 (post-ESS) | 29.2 | 31.9 | p = 0.619 |
| Lund-Kennedy (post-ESS) | 1.0 | 6.1 | p < 0.001 |